Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Invested Capital (2022 - 2025)

Atara Biotherapeutics' Invested Capital history spans 4 years, with the latest figure at -$38.5 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 60.42% year-over-year to -$38.5 million; the TTM value through Dec 2025 reached -$38.5 million, up 60.42%, while the annual FY2025 figure was -$38.5 million, 60.42% up from the prior year.
  • Invested Capital reached -$38.5 million in Q4 2025 per ATRA's latest filing, down from -$36.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $257.5 million in Q2 2022 to a low of -$110.9 million in Q2 2024.
  • Average Invested Capital over 4 years is $22.1 million, with a median of -$35.8 million recorded in 2025.
  • Peak YoY movement for Invested Capital: tumbled 1587.36% in 2024, then soared 68.39% in 2025.
  • A 4-year view of Invested Capital shows it stood at $126.6 million in 2022, then decreased by 21.64% to $99.2 million in 2023, then plummeted by 198.04% to -$97.3 million in 2024, then skyrocketed by 60.42% to -$38.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Invested Capital are -$38.5 million (Q4 2025), -$36.6 million (Q3 2025), and -$35.0 million (Q2 2025).